20D0 Stock Overview
A biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cidara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.40 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$9.20 |
| Beta | 0.99 |
| 11 Month Change | 62.38% |
| 3 Month Change | n/a |
| 1 Year Change | 26.15% |
| 33 Year Change | -35.64% |
| 5 Year Change | -60.95% |
| Change since IPO | -94.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 20D0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 22.4% | -0.7% | 0.2% |
| 1Y | 26.2% | -17.2% | 8.5% |
Return vs Industry: 20D0 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 20D0 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 20D0 volatility | |
|---|---|
| 20D0 Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 20D0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 20D0's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 69 | Jeff Stein | www.cidara.com |
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company’s product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
Cidara Therapeutics, Inc. Fundamentals Summary
| 20D0 fundamental statistics | |
|---|---|
| Market cap | €138.04m |
| Earnings (TTM) | -€119.03m |
| Revenue (TTM) | €42.88m |
3.2x
P/S Ratio-1.2x
P/E RatioIs 20D0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 20D0 income statement (TTM) | |
|---|---|
| Revenue | US$44.65m |
| Cost of Revenue | US$66.31m |
| Gross Profit | -US$21.65m |
| Other Expenses | US$102.30m |
| Earnings | -US$123.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.59 |
| Gross Margin | -48.49% |
| Net Profit Margin | -277.59% |
| Debt/Equity Ratio | 0% |
How did 20D0 perform over the long term?
See historical performance and comparison